Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes.

Abstract

AIM:

To evaluate the efficacy of the short-acting glucagon-like peptide-1 receptor agonist, exenatide, added to insulin therapy in type 1 diabetes on bone mineral density and bone turnover markers.

MATERIALS AND METHODS:

In a randomized, double-blinded, parallel-group trial, 108 individuals with type 1 diabetes aged 18 years or older on basal-bolus therapy with HbA1c 59-88 mmol/mol (7.5%-10.0%) and body mass index of more than 22.0 kg/m2 were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta) before breakfast, lunch, and dinner over 26 weeks as add-on treatment to insulin therapy.

RESULTS:

Exenatide elicited a body weight reduction of 4.4 kg compared with placebo, but no between-group differences in bone mineral density, as assessed by whole-body, hip, lumbar, and forearm dual-energy X-ray absorptiometry following 26 weeks of treatment, were observed. Fasting plasma levels of C-terminal telopeptides of type I collagen, a marker of bone resorption, and amino-terminal propeptide of type I procollagen, a marker of bone formation, were unchanged by exenatide compared with placebo after 26 weeks.

CONCLUSIONS:

Despite an exenatide-induced body weight reduction, no changes in bone metabolism were observed with exenatide added to insulin therapy in type 1 diabetes after 26 weeks.

• Authors: Nicklas J Johansen, Thomas F Dejgaard, Asger Lund, Camilla Schlüntz, Bolette Hartmann, Jens J Holst, Tina Vilsbøll, Henrik U Andersen, Filip K Knop
• Journal: Diabetes, obesity & metabolism (Diabetes Obes Metab) Vol. 24 Issue 2 Pg. 221-227 (02 2022) ISSN: 1463-1326 [Electronic] England
• PMID: 34617375 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 John Wiley & Sons Ltd.

Chemical References

• Blood Glucose
• Glycated Hemoglobin A
• Hypoglycemic Agents
• Insulin
• Venoms
• Exenatide

Topics

• Adolescent
• Blood Glucose (metabolism)
• Diabetes Mellitus, Type 1 (drug therapy)
• Diabetes Mellitus, Type 2 (drug therapy)
• Exenatide (therapeutic use)
• Glycated Hemoglobin (analysis)
• Humans
• Hypoglycemic Agents (pharmacology, therapeutic use)
• Insulin (therapeutic use)
• Venoms (therapeutic use)